{"id":"https://openalex.org/W2883637743","doi":"https://doi.org/10.1002/ajh.25166","title":"Impact of lenalidomide use among non\u2010transfusion dependent patients with myelodysplastic syndromes","display_name":"Impact of lenalidomide use among non\u2010transfusion dependent patients with myelodysplastic syndromes","publication_year":2018,"publication_date":"2018-07-23","ids":{"openalex":"https://openalex.org/W2883637743","doi":"https://doi.org/10.1002/ajh.25166","mag":"2883637743","pmid":"https://pubmed.ncbi.nlm.nih.gov/30033577"},"language":"en","primary_location":{"id":"doi:10.1002/ajh.25166","doi":"https://doi.org/10.1002/ajh.25166","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25166","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25166","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25166","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009387581","display_name":"Andrew Mark Brunner","orcid":"https://orcid.org/0000-0002-2169-4115","observed_orcids":["https://orcid.org/0000-0002-2169-4115"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrew M. Brunner","raw_affiliation_strings":["Massachusetts General Hospital, Boston, Massachusetts"],"raw_orcid":"https://orcid.org/0000-0002-2169-4115","affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111379652","display_name":"Shicheng Weng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shicheng Weng","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110167899","display_name":"Angel M. Cronin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angel Cronin","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010057352","display_name":"Amir Tahmasb Fathi","orcid":"https://orcid.org/0000-0003-4907-6447","observed_orcids":["https://orcid.org/0000-0003-4907-6447"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amir T. Fathi","raw_affiliation_strings":["Massachusetts General Hospital, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047119385","display_name":"Anand R. Habib","orcid":"https://orcid.org/0000-0002-6629-8749","observed_orcids":["https://orcid.org/0000-0002-6629-8749"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anand R. Habib","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Stone","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005090982","display_name":"Tim Graubert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tim Graubert","raw_affiliation_strings":["Massachusetts General Hospital, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090527595","display_name":"David P. Steensma","orcid":"https://orcid.org/0000-0001-5130-9284","observed_orcids":["https://orcid.org/0000-0001-5130-9284"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David P. Steensma","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091710463","display_name":"Gregory Alan Abel","orcid":"https://orcid.org/0000-0003-1100-2813","observed_orcids":["https://orcid.org/0000-0003-1100-2813"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory A. Abel","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5009387581"],"corresponding_institution_ids":["https://openalex.org/I4210087915"],"apc_list":{"value":5450,"currency":"USD","value_usd":5450},"apc_paid":null,"fwci":1.2354,"has_fulltext":true,"cited_by_count":11,"citation_normalized_percentile":{"value":0.79398209,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"93","issue":"9","first_page":"1119","last_page":"1126"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9980000257492065},{"id":"https://openalex.org/keywords/transfusion-dependence","display_name":"transfusion dependence","score":0.8080000281333923},{"id":"https://openalex.org/keywords/transfusion-independence","display_name":"transfusion independence","score":0.8130000233650208},{"id":"https://openalex.org/keywords/off-label-drug-use","display_name":"off-label drug use","score":0.8339999914169312},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8130000233650208},{"id":"https://openalex.org/keywords/thromboembolic-events","display_name":"thromboembolic events","score":0.9549999833106995},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.828000009059906},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.6309999823570251},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5569999814033508}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9884788990020752},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8504583835601807},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.7404041290283203},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6178141832351685},{"id":"https://openalex.org/C2779609412","wikidata":"https://www.wikidata.org/wiki/Q203174","display_name":"Thalidomide","level":3,"score":0.4260942041873932},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.35951125621795654},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.06933236122131348}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001803","descriptor_name":"Blood Transfusion","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009190","descriptor_name":"Myelodysplastic Syndromes","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056687","descriptor_name":"Off-Label Use","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/ajh.25166","doi":"https://doi.org/10.1002/ajh.25166","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25166","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25166","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},{"id":"pmid:30033577","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30033577","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hematology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/ajh.25166","doi":"https://doi.org/10.1002/ajh.25166","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25166","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25166","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G1340853530","display_name":null,"funder_award_id":"RSG\u201014\u2010163\u201001","funder_id":"https://openalex.org/F4320306095","funder_display_name":"American Cancer Society"}],"funders":[{"id":"https://openalex.org/F4320306095","display_name":"American Cancer Society","ror":"https://ror.org/02e463172"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2883637743.pdf","grobid_xml":"https://content.openalex.org/works/W2883637743.grobid-xml"},"referenced_works_count":39,"referenced_works":["https://openalex.org/W187238933","https://openalex.org/W634312238","https://openalex.org/W755414764","https://openalex.org/W1527383154","https://openalex.org/W1966738144","https://openalex.org/W1973018894","https://openalex.org/W1976052439","https://openalex.org/W1994085401","https://openalex.org/W1994881231","https://openalex.org/W2007082803","https://openalex.org/W2009650262","https://openalex.org/W2021333892","https://openalex.org/W2022498718","https://openalex.org/W2043696829","https://openalex.org/W2051228905","https://openalex.org/W2052565988","https://openalex.org/W2081870738","https://openalex.org/W2087821794","https://openalex.org/W2099071696","https://openalex.org/W2104287359","https://openalex.org/W2106584820","https://openalex.org/W2114492363","https://openalex.org/W2118771330","https://openalex.org/W2121533623","https://openalex.org/W2149982846","https://openalex.org/W2160834915","https://openalex.org/W2161821474","https://openalex.org/W2168706693","https://openalex.org/W2178319234","https://openalex.org/W2326121745","https://openalex.org/W2326726820","https://openalex.org/W2338377706","https://openalex.org/W2400514548","https://openalex.org/W2463012969","https://openalex.org/W2467917196","https://openalex.org/W2559601897","https://openalex.org/W2567369862","https://openalex.org/W2765144049","https://openalex.org/W4231981436"],"related_works":["https://openalex.org/W2051228905","https://openalex.org/W2979951375","https://openalex.org/W2892132550","https://openalex.org/W306108555","https://openalex.org/W1959361668","https://openalex.org/W1804712856","https://openalex.org/W2979492810","https://openalex.org/W2021333892","https://openalex.org/W4281257696","https://openalex.org/W2429774828"],"abstract_inverted_index":{"Chemotherapies":[0],"approved":[1,17],"for":[2,18,66,97,134],"defined":[3],"subgroups":[4],"promise":[5],"personalized":[6],"oncologic":[7],"care,":[8],"but":[9,27],"their":[10],"off-label":[11],"impact":[12],"is":[13,16],"unclear.":[14],"Lenalidomide":[15],"lower-risk,":[19],"transfusion-dependent":[20],"(TD)":[21],"myelodysplastic":[22],"syndromes":[23],"(MDS)":[24],"with":[25,44,51,189,210,230],"del(5q),":[26],"frequently":[28],"used":[29],"in":[30,149,248],"MDS":[31,52,179,183],"outside":[32],"this":[33],"indication.":[34],"We":[35,93,113],"characterized":[36],"lenalidomide":[37,68,101,146,174,185,226],"use":[38],"and":[39,55,70,87,110,125,151,204],"outcomes":[40],"among":[41,143,160,227],"non-TD":[42,98,152,161,171,234],"patients":[43,99,116,144,162,172,197,229,235,240],"MDS.":[45],"Patients":[46],"65":[47],"or":[48,253],"older":[49],"diagnosed":[50],"between":[53],"2007":[54],"2013":[56],"were":[57,64,83,147,158],"identified":[58,114],"using":[59],"SEER;":[60],"linked":[61],"Medicare":[62],"claims":[63,133],"evaluated":[65],"transfusions,":[67],"use,":[69],"incident":[71,155],"toxicities.":[72],"TD":[73,124,150,196,228],"was":[74,186],"\u22652":[75],"transfusion":[76,84,89,136,251],"episodes":[77],"within":[78,175],"an":[79],"8-week":[80],"period;":[81],"responses":[82],"independence":[85],"(TI)":[86],"\u226550%":[88],"reduction":[90],"(minor":[91],"response).":[92],"compared":[94],"overall":[95,254],"survival":[96],"receiving":[100,105,139,173],"versus":[102],"those":[103],"not":[104,187],"lenalidomide,":[106,120],"matched":[107],"on":[108],"disease":[109],"patient":[111],"characteristics.":[112],"676":[115],"who":[117],"had":[118,131],"received":[119,237],"including":[121],"275":[122],"(40.7%)":[123],"401":[126],"(59.3%)":[127],"non-TD;":[128],"18.5%":[129],"(125/676)":[130],"zero":[132],"RBC":[135],"prior":[137],"to":[138,181,214],"lenalidomide.":[140,238],"Incident":[141],"toxicities":[142],"prescribed":[145],"similar":[148],"groups,":[153],"except":[154],"thromboembolic":[156],"events":[157],"higher":[159],"(10.8%":[163],"vs.":[164],"6.0%,":[165],"P":[166],"=":[167,193,199],".04).":[168],"Comparing":[169],"191":[170],"6":[176],"months":[177],"of":[178,216,225,246,250],"diagnosis":[180],"risk-matched":[182],"controls,":[184],"associated":[188],"improved":[190],"OS":[191],"(P":[192],".78).":[194],"Among":[195],"(n":[198],"275),":[200],"31%":[201],"achieved":[202,206],"TI,":[203],"30%":[205],"minor":[207],"hematologic":[208],"response,":[209],"a":[211],"median":[212],"time":[213],"TI":[215],"4.1":[217],"weeks.":[218],"In":[219],"conclusion,":[220],"we":[221],"confirmed":[222],"the":[223],"benefit":[224,247],"MDS;":[231],"however,":[232],"many":[233],"also":[236],"These":[239],"experienced":[241],"accompanying":[242],"toxicity":[243],"without":[244],"evidence":[245],"terms":[249],"needs":[252],"survival.":[255]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2018-08-03T00:00:00"}